Name: 글로벌 시장 동향
SKU: PH2241
Availability: InStock

보고서 요약(국문)

개요
전 세계 불면증 치료 시장은 2022년 37억 달러 규모에 달했으며, 2023년부터 2030년까지 연평균 4.3%의 성장률을 보이며 2030년에는 51억 달러에 이를 것으로 예상됩니다.
불면증은 잠들기 어렵거나, 잠을 유지하기 어렵거나, 숙면을 취하기 어려운 수면 장애입니다. 단기 불면증은 스트레스, 생활 패턴 또는 환경 변화로 인해 발생하며 며칠 또는 몇 주 동안 지속될 수 있습니다. 만성 또는 장기 불면증은 일주일에 3일 이상 또는 3개월 이상 지속되는 경우를 말합니다.
전 세계 불면증 치료 시장은 에스타졸람, 테마제팜, 퀘자팜과 같은 벤조디아제핀 계열 약물의 사용 증가로 인해 최근 몇 년간 상당한 성장을 보였습니다. 테마제팜은 불면증 치료에 가장 흔하게 처방되는 벤조디아제핀 계열 약물입니다. 불면증 치료제 선택은 원하는 작용 발현 시간과 지속 시간에 따라 결정됩니다.

또한, 스트레스 수준 증가, 신제품 출시, 연구 개발 투자 증가와 같은 주요 성장 동력이 향후 시장 성장을 견인할 것으로 예상됩니다. Merck & Co., Pfizer Inc., Abbott, Eisai Ltd., Idorsia Pharmaceuticals 등 주요 기업들이 활발하게 시장에서 활동하고 있습니다.
시장 동향
스트레스 수준 증가가 시장 성장을 촉진할 것으로 예상됩니다.
전 세계적으로 스트레스 수준이 높아지고 있는 것이 주요 성장 동력입니다. 스트레스와 불안은 불면증으로 이어지는 경우가 많으며, 스트레스가 많은 삶의 사건이나 트라우마는 수면 장애의 주요 원인입니다. 불안하고 반추적인 성격 특성, 스트레스 사건 등 여러 심리적, 생리적 요인이 불면증의 발생 및 지속에 영향을 미칩니다.
예를 들어, 2021년 12월에 발표된 영국 산업안전보건청(HSE) 보고서에 따르면, 2020-2021년 동안 82만 2천 명 이상의 근로자가 업무 관련 스트레스, 우울증 또는 불안을 겪었습니다. 과도한 직업 스트레스를 경험했다고 응답한 근로자는 32.8%였습니다. 응답자의 절반 이상(51%)이 우울 증상을 보고했으며, 약 11%는 불면증 진단을 받았다고 보고했습니다.
FDA의 불면증 치료제 승인 증가로 시장 성장 촉진 예상
규제 기관의 치료제 승인 증가는 시장 성장을 견인하는 요인입니다. FDA 승인 절차는 일반적으로 질병의 동물 모델을 이용한 전임상 실험을 포함합니다. 동물 모델 실험 결과가 긍정적이면 FDA는 제안된 중재 연구 구조를 승인할 수 있습니다.
예를 들어, 2022년 12월, Zydus Lifesciences Ltd는 불면증의 단기 치료에 사용되는 트리아졸람 정제의 제네릭 버전을 미국 FDA로부터 시판 최종 승인받았습니다. 이 약은 불면증 및 수면 장애(수면 시작 또는 유지 어려움) 치료에 단기간 사용됩니다. 뇌 활동을 억제하여 수면을 유도하는 방식으로 작용합니다.
불면증 치료제 관련 부작용
일반 의약품 수면제는 변비, 구강 건조, 두통, 소화 장애를 유발할 수 있습니다. 클리블랜드 클리닉에 따르면, 수면제를 복용한 사람 10명 중 약 8명이 다음 날 숙취와 같은 증상을 경험합니다. 이는 졸음, 사고력 저하, 어지럼증 또는 균형 장애로 이어집니다.
이러한 주간 증상은 운전, 업무, 일상생활 수행 능력에 부정적인 영향을 미칠 수 있습니다. 일부 처방 수면제는 수면장애를 유발할 수 있으며, 이 수면 장애는 수면 중에 위험한 행동을 초래할 수 있습니다. 따라서 위와 같은 요인으로 인해 시장은 예측 기간 동안 성장이 둔화될 것으로 예상됩니다.

본 보고서에 대한 자세한 내용은 샘플을 요청하십시오.
세그먼트 분석
세계 불면증 치료 시장은 유형, 치료 방법, 유통 채널 및 지역별로 세분화됩니다.
유형 부문 중 만성 불면증이 세계 불면증 치료 시장 점유율의 약 47.3%를 차지했습니다.
전 세계적으로 치료제 승인이 증가함에 따라 불면증 치료 시장의 수요가 증가하고 있습니다. 예를 들어, 2023년 6월 이도르시아(Idorsia Ltd)는 스위스에서 만성 불면증 치료제인 큐비비크(QUVIVIQ, 다리도렉산트)를 출시했습니다. 큐비비크는 야간 증상과 주간 기능을 모두 개선하는 최초의 만성 불면증 치료제입니다. 큐비비크는 스위스에서 만성 불면증 치료에 사용 가능한 최초의 이중 오렉신 수용체 길항제(DORA)입니다.
또한, 2021년 2월 에자이(Eisai Co., Ltd.)와 그 홍콩 자회사인 에자이(홍콩)(Eisai (Hong Kong) Co., Ltd.)는 자체 개발한 오렉신 수용체 길항제인 데이비고(DAYVIGO, 일반명: 렘보렉산트)에 대해 수면 시작이나 수면 유지에 어려움을 겪는 성인 만성 불면증 치료제로 승인을 받았습니다.

지리적 시장 침투
북미는 2022년 시장 점유율의 약 38.4%를 차지했습니다.
북미는 최근 몇 년간 불면증 치료 시장에서 상당한 비중을 차지해 왔으며, 수면 장애 유병률 증가, 불면증 관련 기관의 설립, 불면증 치료 연구 개발 등의 요인으로 인해 이러한 추세는 예측 기간 동안 지속될 것으로 예상됩니다.
예를 들어, 2023년 수면 재단(Sleep Foundation) 자료에 따르면 미국에서는 약 5천만 명에서 7천만 명이 만성 수면 장애를 겪고 있는 것으로 추산됩니다. 미국 성인의 약 9%에서 15%는 불면증으로 인해 주간 활동에 지장을 받고 있습니다. 이 중 여성은 남성보다 불면증을 겪을 확률이 40% 더 높습니다.

경쟁 환경
시장의 주요 글로벌 업체로는 Merck & Co., Pfizer Inc., Abbott, Genentech, LGM Pharma, Sigma Aldrich Sanofi S.A, Takeda Pharmaceuticals, Eisai Ltd., Idorsia Pharmaceuticals 등이 있습니다.
COVID-19 영향 분석
COVID-19 팬데믹은 불면증 치료 시장에 상당한 영향을 미쳤습니다. 팬데믹이 한창일 때 많은 의료 시스템이 과부하 상태에 빠졌고, 긴급하지 않은 의료 시술 및 검진이 연기되거나 취소되었습니다. 이로 인해 불면증 치료 연구 및 제품 출시가 지연되었습니다. 임상 시험은 불면증 치료 시장에서 새로운 치료법을 개발하고 치료 결과를 개선하는 데 필수적입니다.
하지만 팬데믹으로 인해 많은 임상 시험 기관이 환자 안전을 최우선으로 고려하여 등록을 일시적으로 중단하거나 프로토콜을 변경하면서 임상 시험 진행에 차질이 생겼습니다. 이로 인해 시험 완료 및 새로운 치료법의 출시가 지연되었습니다. 더욱이, 팬데믹 기간 동안 연구 개발 노력의 초점이 코로나19 백신 및 치료제 개발에 집중되면서 불면증 치료 시장은 예측 기간 동안 다소 영향을 받을 것으로 예상됩니다.

유형별 분류
• 급성 불면증
• 만성 불면증

• 발병 불면증

• 유지 불면증

• 아동기 행동성 불면증
약물별
• 에스조피클론
• 라멜테온
• 잘레플론
• 졸피뎀
• 에스타졸람
• 기타
유통 채널별
• 병원 약국
• 소매 약국
• 온라인 약국
• 기타
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
주요 개발 사항
• 2022년 6월, Pear Therapeutics는 만성 불면증 성인을 위한 처방 디지털 치료제인 Somryst에 대해 FDA의 판매 허가를 받았습니다. 이 치료법은 불면증 환자를 위한 인지행동치료(CBTi)와 개인 맞춤형 알고리즘 기반 수면 제한 권장 사항을 함께 제공합니다.
• 2022년 4월, 북광제약은 불면증 환자 치료용 잘레딥 캡슐을 출시했는데, 이는 한국 최초로 잘레플론을 주성분으로 사용하는 불면증 치료제입니다.

보고서 구매 이유:

• 유형, 약물, 유통 채널 및 지역별 글로벌 불면증 치료 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악하기 위해

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴하기 위해

• 모든 세그먼트를 포함한 글로벌 불면증 치료 시장 수준의 다양한 데이터가 담긴 엑셀 시트 제공

• 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석이 담긴 PDF 보고서 제공

• 주요 기업의 핵심 제품 정보를 담은 엑셀 파일 제공

글로벌 불면증 치료 시장 보고서는 약 69개의 표, 70개의 그림, 195페이지 분량입니다.

2023년 목표 고객층
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Insomnia Treatment Market reached US$ 3.7 billion in 2022 and is expected to reach US$ 5.1 billion by 2030 growing with a CAGR of 4.3% during the forecast period 2023-2030.
Insomnia is a sleep disorder that trouble falling asleep, staying asleep, and getting good quality sleep. Short-term insomnia is caused by stress or changes in the schedule or environment and this can last for a few days or weeks. Chronic or long-term insomnia occurs 3 or more nights a week or lasts more than 3 months.
The global insomnia treatment market has witnessed significant growth in recent years due to the intake of benzodiazepine drugs such as estazolam, temazepam, and quazepam. Temazepam is the most commonly prescribed benzodiazepine drug for insomnia. The choice of insomnia drug is based on the desired onset and duration of action.
Furthermore, significant growth drivers such as increasing stress levels, product launches, and rising research and developments give rise to future market growth. Significant key players like Merck & Co., Pfizer Inc., Abbott, Eisai Ltd., Idorsia Pharmaceuticals, and others are actively operating in the market.
Dynamics
Rising Stress Levels Among People is Expected to Boost the Market Growth
The rising stress levels among people across the globe act as a primary driver. Stress and anxiety often lead to insomnia and stressful life events or trauma are the main causes of sleeping disorders. Several psychological and physiological factors contribute to the onset and perpetuation of insomnia, such as anxious-ruminative personality traits, and stressful events.
For instance, According to the Health and Safety Executive report published in December 2021, over 822,000 workers suffered from work-related stress, depression, or anxiety in 2020-2021. Excessive occupational stress reported by the employees was 32.8%. More than half of respondents (51%) reported depressive symptoms and around 11% reported being diagnosed with insomnia.
Rising FDA Approvals for Insomnia Treatment is Expected to Boost the Market Growth
The increase in treatment approvals by regulatory bodies helps to drive market growth. The process of getting approval from the FDA generally involves preclinical experiments in an animal model of the disease. If the results of the animal model experiments are favorable then the FDA can approve the proposed structure of an interventional study.
For instance, in December 2022, Zydus Lifesciences Ltd received final approval from the US FDA to market its generic version of Triazolam tablets used on a short-term basis to treat insomnia. The medicine is used on a short-term basis to treat insomnia and difficulty falling asleep or staying asleep. It works by slowing activity in the brain to allow sleep.
Side Effects Associated with Insomnia Drugs
Over-the-counter prescription sleeping pills can cause constipation, dry mouth, headaches, and digestive problems. According to Cleveland Clinic, approximately 8 out of 10 people experience a hangover effect the day after taking sleep medicine. It leads to drowsiness, muddled thinking, and experience dizziness or balance problems.
These daytime effects can negatively impact the ability to drive, work, and complete daily tasks. Few prescription sleep medicines can bring on parasomnia and this disruptive sleep disorder can cause dangerous behaviors while the person is still mostly asleep. Hence, owing to the above factors, the market is expected to hamper over the forecast period.
For more details on this report – Request for Sample
Segment Analysis
The global insomnia treatment market is segmented based on type, treatment, distribution channel and region.
Chronic Insomnia from the Type Segment Accounted for Approximately 47.3% of the Global Insomnia Treatment Market Share
The rising treatment drug approvals globally have contributed to the growing demand for the insomnia treatment market. For instance, in June 2023, Idorsia Ltd launched QUVIVIQ (daridorexant) in Switzerland which is a first-in-class treatment for chronic insomnia disorder to improve both nighttime symptoms and daytime functioning. QUVIVIQ is the first dual orexin receptor antagonist (DORA) available in Switzerland for the treatment of chronic insomnia disorder.
Additionally, in February 2021, Eisai Co., Ltd., its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. obtained approval for the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with chronic insomnia which is characterized by difficulties with sleep onset or sleep maintenance.
Geographical Penetration
North America Accounted for Approximately 38.4% of the Market Share in 2022
North America has maintained a significant proportion of the insomnia treatment market in recent years, and this trend is anticipated to continue throughout the forecast period due to factors such as the rising prevalence of sleep disorders, organizations specific to insomnia, and research and developments in insomnia treatment.
For instance, according to the Sleep Foundation data published in 2023, it estimates around 50 million to 70 million people in the U.S. have ongoing sleep disorders. Approximately, 9% to 15% of U.S. adults have insomnia that affects their daytime activities. Among them, 40% of women are more likely to have insomnia than men.
Competitive Landscape
The major global players in the market include Merck & Co., Pfizer Inc., Abbott, Genentech, LGM Pharma, Sigma Aldrich Sanofi S.A, Takeda Pharmaceuticals, Eisai Ltd., Idorsia Pharmaceuticals. among others.
COVID-19 Impact Analysis
The COVID-19 pandemic has had a significant impact on the insomnia treatment market. During the height of the pandemic, many healthcare systems were overwhelmed, and non-urgent medical procedures and screenings were postponed or canceled. This led to delays in insomnia treatment research and product launches. Clinical trials are vital for developing new treatments and improving outcomes in the insomnia treatment market.
However, the pandemic disrupted the conduct of clinical trials, with many sites temporarily halting enrollment or modifying protocols to prioritize patient safety. This has led to delays in the completion of trials and the availability of new therapies. Moreover, the focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. Therefore, owing to the above factors, the insomnia treatment market is expected to be moderately affected over the forecast period.
By Type
• Acute Insomnia
• Chronic Insomnia.
• Onset Insomnia.
• Maintenance Insomnia.
• Behavioral Insomnia of Childhood
By Drugs
• Eszopiclone
• Ramelteon
• Zaleplon
• Zolpidem
• Estazolam
• Others
By Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In June 2022, Pear Therapeutics received marketing authorization from the FDA for Somryst, its prescription digital therapeutic for adults with chronic insomnia. The treatment provides cognitive behavioral therapy for insomnia (CBTi) alongside personalized, algorithm-generated sleep restriction recommendations.
• In April 2022, Bukwang Pharmaceutical launched the Zaledeep Cap for the treatment of insomnia patients which is the first treatment in Korea that uses zaleplon as a main ingredient.
Why Purchase the Report?
• To visualize the global insomnia treatment market segmentation based on type, drugs, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global insomnia treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global insomnia treatment market report would provide approximately 69 tables, 70 figures, and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Drugs
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising stress levels among people
4.1.1.2. Increasing FDA approvals for insomnia treatment
4.1.2. Restraints
4.1.2.1. Side effects associated with insomnia drugs
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Acute Insomnia
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Chronic Insomnia
7.4. Onset Insomnia
7.5. Maintenance Insomnia
7.6. Behavioral Insomnia of Childhood
8. By Drugs
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
8.1.2. Market Attractiveness Index, By Drugs
8.2. Eszopiclone
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Ramelteon
8.4. Zaleplon
8.5. Zolpidem
8.6. Estazolam
8.7. Others
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacy
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacy
9.4. Online Pharmacy
9.5. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. U.K.
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Product Benchmarking
11.3. Company Share Analysis
11.4. Key Developments and Strategies
12. Company Profiles
12.1. Merck & Co.*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Pfizer Inc.
12.3. Abbott
12.4. Genentech
12.5. LGM Pharma
12.6. Sigma Aldrich
12.7. Sanofi S.A
12.8. Takeda Pharmaceuticals
12.9. Eisai Ltd.
12.10. Idorsia Pharmaceuticals
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Merck & Co., 4.	Key Developments, Pfizer Inc., Abbott, Genentech, LGM Pharma, Sigma Aldrich, Sanofi S.A, Takeda Pharmaceuticals, Eisai Ltd., Idorsia Pharmaceuticals

표 목록 (Tables)

List of Tables

Table 1 Global Insomnia Treatment Market Value, By Type, 2023, 2027 & 2031 (US$ Billion)

Table 2 Global Insomnia Treatment Market Value, By Drugs, 2023, 2027 & 2031 (US$ Billion)

Table 3 Global Insomnia Treatment Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Billion)

Table 4 Global Insomnia Treatment Market Value, By Region, 2023, 2027 & 2031 (US$ Billion)

Table 5 Global Insomnia Treatment Market Value, By Type, 2023, 2027 & 2031 (US$ Billion)

Table 6 Global Insomnia Treatment Market Value, By Type, 2022-2031 (US$ Billion)

Table 7 Global Insomnia Treatment Market Value, By Drugs, 2023, 2027 & 2031 (US$ Billion)

Table 8 Global Insomnia Treatment Market Value, By Drugs, 2022-2031 (US$ Billion)

Table 9 Global Insomnia Treatment Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Billion)

Table 10 Global Insomnia Treatment Market Value, By Distribution Channel, 2022-2031 (US$ Billion)

Table 11 Global Insomnia Treatment Market Value, By Region, 2023, 2027 & 2031 (US$ Billion)

Table 12 Global Insomnia Treatment Market Value, By Region, 2022-2031 (US$ Billion)

Table 13 North America Insomnia Treatment Market Value, By Type, 2022-2031 (US$ Billion)

Table 14 North America Insomnia Treatment Market Value, By Drugs, 2022-2031 (US$ Billion)

Table 15 North America Insomnia Treatment Market Value, By Distribution Channel, 2022-2031 (US$ Billion)

Table 16 North America Insomnia Treatment Market Value, By Country, 2022-2031 (US$ Billion)

Table 17 South America Insomnia Treatment Market Value, By Type, 2022-2031 (US$ Billion)

Table 18 South America Insomnia Treatment Market Value, By Drugs, 2022-2031 (US$ Billion)

Table 19 South America Insomnia Treatment Market Value, By Distribution Channel, 2022-2031 (US$ Billion)

Table 20 South America Insomnia Treatment Market Value, By Country, 2022-2031 (US$ Billion)

Table 21 Europe Insomnia Treatment Market Value, By Type, 2022-2031 (US$ Billion)

Table 22 Europe Insomnia Treatment Market Value, By Drugs, 2022-2031 (US$ Billion)

Table 23 Europe Insomnia Treatment Market Value, By Distribution Channel, 2022-2031 (US$ Billion)

Table 24 Europe Insomnia Treatment Market Value, By Country, 2022-2031 (US$ Billion)

Table 25 Asia-Pacific Insomnia Treatment Market Value, By Type, 2022-2031 (US$ Billion)

Table 26 Asia-Pacific Insomnia Treatment Market Value, By Drugs, 2022-2031 (US$ Billion)

Table 27 Asia-Pacific Insomnia Treatment Market Value, By Distribution Channel, 2022-2031 (US$ Billion)

Table 28 Asia-Pacific Insomnia Treatment Market Value, By Country, 2022-2031 (US$ Billion)

Table 29 Middle East & Africa Insomnia Treatment Market Value, By Type, 2022-2031 (US$ Billion)

Table 30 Middle East & Africa Insomnia Treatment Market Value, By Drugs, 2022-2031 (US$ Billion)

Table 31 Middle East & Africa Insomnia Treatment Market Value, By Distribution Channel, 2022-2031 (US$ Billion)

Table 32 Merck & Co.: Overview

Table 33 Merck & Co.: Product Portfolio

Table 34 Merck & Co.: Key Developments

Table 35 Pfizer Inc.: Overview

Table 36 Pfizer Inc.: Product Portfolio

Table 37 Pfizer Inc.: Key Developments

Table 38 Abbott: Overview

Table 39 Abbott: Product Portfolio

Table 40 Abbott: Key Developments

Table 41 Genentech: Overview

Table 42 Genentech: Product Portfolio

Table 43 Genentech: Key Developments

Table 44 LGM Pharma: Overview

Table 45 LGM Pharma: Product Portfolio

Table 46 LGM Pharma: Key Developments

Table 47 Sigma Aldrich: Overview

Table 48 Sigma Aldrich: Product Portfolio

Table 49 Sigma Aldrich: Key Developments

Table 50 Sanofi S.A: Overview

Table 51 Sanofi S.A: Product Portfolio

Table 52 Sanofi S.A: Key Developments

Table 53 Takeda Pharamceuticals: Overview

Table 54 Takeda Pharamceuticals: Product Portfolio

Table 55 Takeda Pharamceuticals: Key Developments

Table 56 Eisai Ltd.: Overview

Table 57 Eisai Ltd.: Product Portfolio

Table 58 Eisai Ltd.: Key Developments

Table 59 Idorsia Pharmaceuticals: Overview

Table 60 Idorsia Pharmaceuticals: Product Portfolio

Table 61 Idorsia Pharmaceuticals: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Insomnia Treatment Market Value, 2022-2031 (US$ Billion)

Figure 2 Global Insomnia Treatment Market Share, By Type, 2022 & 2031 (%)

Figure 3 Global Insomnia Treatment Market Share, By Drugs, 2022 & 2031 (%)

Figure 4 Global Insomnia Treatment Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 5 Global Insomnia Treatment Market Share, By Region, 2022 & 2031 (%)

Figure 6 Global Insomnia Treatment Market Y-o-Y Growth, By Type, 2022-2030 (%)

Figure 7 Acute Insomnia Insomnia Treatment Market Value, 2022-2031 (US$ Billion)

Figure 8 Chronic Insomnia Insomnia Treatment Market Value, 2022-2031 (US$ Billion)

Figure 9 Onset Insomnia Insomnia Treatment Market Value, 2022-2031 (US$ Billion)

Figure 10 Maintenance Insomnia Insomnia Treatment Market Value, 2022-2031 (US$ Billion)

Figure 11 Behavioral Insomnia of Childhood Insomnia Treatment Market Value, 2022-2031 (US$ Billion)

Figure 12 Global Insomnia Treatment Market Y-o-Y Growth, By Drugs, 2022-2030 (%)

Figure 13 Eszopiclone Drugs in Global Insomnia Treatment Market Value, 2022-2031 (US$ Billion)

Figure 14 Ramelteon Drugs in Global Insomnia Treatment Market Value, 2022-2031 (US$ Billion)

Figure 15 Zaleplon Drugs in Global Insomnia Treatment Market Value, 2022-2031 (US$ Billion)

Figure 16 Zolpidem Drugs in Global Insomnia Treatment Market Value, 2022-2031 (US$ Billion)

Figure 17 Estazolam Drugs in Global Insomnia Treatment Market Value, 2022-2031 (US$ Billion)

Figure 18 Others Drugs in Global Insomnia Treatment Market Value, 2022-2031 (US$ Billion)

Figure 19 Global Insomnia Treatment Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 20 Hospital Pharmacy Distribution Channel in Global Insomnia Treatment Market Value, 2022-2031 (US$ Billion)

Figure 21 Retail Pharmacy Distribution Channel in Global Insomnia Treatment Market Value, 2022-2031 (US$ Billion)

Figure 22 Online Pharmacy Distribution Channel in Global Insomnia Treatment Market Value, 2022-2031 (US$ Billion)

Figure 23 Others Distribution Channel in Global Insomnia Treatment Market Value, 2022-2031 (US$ Billion)

Figure 24 Global Insomnia Treatment Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 25 North America Insomnia Treatment Market Value, 2022-2031 (US$ Billion)

Figure 26 Asia-Pacific Insomnia Treatment Market Value, 2022-2031 (US$ Billion)

Figure 27 Europe Insomnia Treatment Market Value, 2022-2031 (US$ Billion)

Figure 28 South America Insomnia Treatment Market Value, 2022-2031 (US$ Billion)

Figure 29 Middle East and Africa Insomnia Treatment Market Value, 2022-2031 (US$ Billion)

Figure 30 North America Insomnia Treatment Market Value, 2022-2031 (US$ Billion)

Figure 31 North America Insomnia Treatment Market Share, By Type, 2022 & 2031 (%)

Figure 32 North America Insomnia Treatment Market Share, By Drugs, 2022 & 2031 (%)

Figure 33 North America Insomnia Treatment Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 34 North America Insomnia Treatment Market Share, By Country, 2022 & 2031 (%)

Figure 35 South America Insomnia Treatment Market Value, 2022-2031 (US$ Billion)

Figure 36 South America Insomnia Treatment Market Share, By Type, 2022 & 2031 (%)

Figure 37 South America Insomnia Treatment Market Share, By Drugs, 2022 & 2031 (%)

Figure 38 South America Insomnia Treatment Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 39 South America Insomnia Treatment Market Share, By Country, 2022 & 2031 (%)

Figure 40 Europe Insomnia Treatment Market Value, 2022-2031 (US$ Billion)

Figure 41 Europe Insomnia Treatment Market Share, By Type, 2022 & 2031 (%)

Figure 42 Europe Insomnia Treatment Market Share, By Drugs, 2022 & 2031 (%)

Figure 43 Europe Insomnia Treatment Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 44 Europe Insomnia Treatment Market Share, By Country, 2022 & 2031 (%)

Figure 45 Asia-Pacific Insomnia Treatment Market Value, 2022-2031 (US$ Billion)

Figure 46 Asia-Pacific Insomnia Treatment Market Share, By Type, 2022 & 2031 (%)

Figure 47 Asia-Pacific Insomnia Treatment Market Share, By Drugs, 2022 & 2031 (%)

Figure 48 Asia-Pacific Insomnia Treatment Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 49 Asia-Pacific Insomnia Treatment Market Share, By Country, 2022 & 2031 (%)

Figure 50 Middle East & Africa Insomnia Treatment Market Value, 2022-2031 (US$ Billion)

Figure 51 Middle East & Africa Insomnia Treatment Market Share, By Type, 2022 & 2031 (%)

Figure 52 Middle East & Africa Insomnia Treatment Market Share, By Drugs, 2022 & 2031 (%)

Figure 53 Middle East & Africa Insomnia Treatment Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 54 Merck & Co.: Financials

Figure 55 Pfizer Inc.: Financials

Figure 56 Abbott: Financials

Figure 57 Genentech: Financials

Figure 58 LGM Pharma: Financials

Figure 59 Sigma Aldrich: Financials

Figure 60 Sanofi S.A: Financials

Figure 61 Takeda Pharamceuticals: Financials

Figure 62 Eisai Ltd.: Financials

Figure 63 Idorsia Pharmaceuticals: Financials

세계 불면증 치료 시장 – 2023-2030

Global Insomnia Treatment Market - 2023-2030